The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease.

Content Provider	Europe PMC
Author	Nicolaides, Andrew N.
Abstract	At the 2019 European Venous Forum in Zurich Switzerland, a symposium entitled “State of the art: benefits of MPFF throughout CVD progression” was held to discuss the developing treatment strategies for patients at all stages of chronic venous disease (CVD). At the early stages of CVD, management should be focused on preventing disease progression through lifestyle changes and conservative treatment; treatment can also include venoactive drugs (VAD) such as micronized purified flavonoid fraction (MPFF; Daflon®), which is the most well-known and most widely prescribed VAD in Europe. As the disease progresses, patients who require interventional procedures (e.g., endovenous procedure or sclerotherapy) can also benefit from MPFF treatment in the recovery period after the procedure, as MPFF has been shown to reduce periprocedural pain and bleeding (hematoma), and to improve CVD symptoms during this period. Management of CVD in patients with venous leg ulcers (VLU) is the most challenging; in these patients, recommended adjunct therapies to be combined with standard compression therapy include VAD (MPFF) and non-VAD drugs (pentoxifylline and sulodexide) which have been shown to speed VLU healing in comparison with compression therapy alone.
ISSN	0741238X
Journal	Advances in Therapy
Volume Number	37
PubMed Central reference number	PMC7004432
Issue Number	suppl 1
PubMed reference number	31970659
e-ISSN	18658652
DOI	10.1007/s12325-019-01218-8
Language	English
Publisher	Springer Healthcare
Publisher Date	2020-01-22
Publisher Place	Cheshire
Access Restriction	Open
Rights License	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. © The Author(s) 2020
Subject Keyword	Chronic venous disease Chronic venous reflux Endovenous ablation Sclerotherapy Venoactive drugs Venous leg ulcers
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)